Biospecimen Availability Overview
The table below provides an overview of what types of biospecimens are available in each cohort study.
Cohort | Population | Research Intent | DNA | RNA | CSF | Whole Blood | Plasma | Serum | Urine | Peripheral Mononuclear Blood Cells |
---|---|---|---|---|---|---|---|---|---|---|
NINDS Parkinson's disease Biomarkers Program (PDBP) | Early to advance PD and controls | |||||||||
24-Hour Biofluid Sampling | Early to moderate PD and controls | Biomarker discovery | ||||||||
BioFind | Moderate to advanced PD and controls | Biomarker discovery | ||||||||
DATATOP | Early, unmedicated PD | Biomark discovery and validation | ||||||||
FS-ZONE | 217 individuals with early PD | Phase II placebo-controlled study of the safety and effect of two dosages of oral pioglitazone | ||||||||
LRRK2 Cohort | Biomarker discovery | Biomarker discovery | ||||||||
STEADY-III | 336 subjects with early idiopathic PD not requiring dopaminergic therapy | Pharmacogenetics/pharmacodynamics | ||||||||
SURE-PD3 | 298 Individuals with early Parkinson's Disease | Pharmacogenetics/pharmacodynamics | ||||||||
SURE-PD2 | 75 individuals with early Parkinson's Disease | Pharmacogenetics/pharmacodynamics | ||||||||
Nilo-PD | 76 individuals with moderate to advanced PD | Assay development, biomarker discovery, pharmacogenetics/pharmacodynamics, biomarker replication & validation | ||||||||
CERE-120 | 148 individuals with PD | Assay development, biomarker discovery, pharmacogenetics/pharmacodynamics | ||||||||
AVE-8112 | 13 individuals with PD | Assay development, biomarker discovery, pharmacogenetics/pharmacodynamics |